


Cys-mc-MMAE

Cat. No.:	HY-157284
Molecular Formula:	C ₅₂ H ₈₅ N ₇ O ₁₂ S
Molecular Weight:	1032.34
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (96.87 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	0.9687 mL	4.8434 mL	9.6867 mL
		5 mM	0.1937 mL	0.9687 mL	1.9373 mL
	10 mM	0.0969 mL	0.4843 mL	0.9687 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.42 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.42 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.42 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs ^[1] .
--------------------	--

REFERENCES

[1]. Wang Y, et al. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety. *Cancers (Basel)*. 2020 Mar 21;12(3):744.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA